AKT1 and Parkinson disease: Shikonin inhibits oxidative stress and neuroinflammation by regulating the AKT/ERK/JNK/NF-κB pathway and improves apoptosis of the dopaminergic neurons in PD patients, which improves upon the evidence of Parkinson’s disease-induced pathology, as well as cognitive deficits.